A Phase 4 interventional study of Paracetamol and caffeine and Paracetamol in Pain, sponsored by GlaxoSmithKline. Terminated at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-08-28.
Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 137 studies testing acetaminophen in Pain — 5 open to participants now, 5 under way, none of them phase 3. Acetaminophen · Pain.
Among the 137 studies testing acetaminophen in Pain, this one is the 119th largest by enrollment, is one of 9 that started in 2016, is one of 67 in phase 4, and was the 94th registered.
10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.
Browse Pain studies →5 of the 137 studies testing acetaminophen in Pain are open now, in 3 countries. Recruiting first, the newest first:
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18+
Horizon Health Network · Sites in Canada
Ages 19+
University of Gaziantep · Sites in Turkey
Ages 18–75
Western Galilee Hospital-Nahariya · Sites in Israel
Ages 18–45 · Women only · Healthy volunteers
Baskent University · Sites in Turkey
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →
Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
137 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 18 · Phase 3 25 · Phase 4 67
First in 2003; this study’s year is marked. 9 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 21 is below the median of 66 across 8,505 interventional studies indexed under Pain.
Median enrollment 95 across the 137 interventional studies. Of the 115 that completed or were terminated, 53 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 137 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
30 studies in Pain by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 30 finished, 15 (50%) have results posted.
Among the 30 studies in Pain by GlaxoSmithKline, this one is the 24th largest by enrollment, is one of 2 that started in 2016, is one of 3 in phase 4, and was the 23rd registered.
GlaxoSmithKline’s Pain studies by the year they started, since 2003.
4 of the studies testing acetaminophen in Pain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07512297University of GaziantepPain Control During ESWL Using Non-Opioid Analgesics | 2027-01-01 |
| NCT07368738Horizon Health NetworkIntravenous Acetaminophen and Ketorolac for Pain Management During Extracorporeal Shockwave Lithotripsy | 2027-04 |
| NCT06613178McGill University Health Centre/Research Institute of the McGill University Health CentreIntravenous Acetaminophen After Cardiac Surgery - Definitive Study | 2027-07-01 |
| NCT07536425Western Galilee Hospital-NahariyaPreoperative Indomethacin and Paracetamol for Pain Management During Oocyte Retrieval in IVF Patients | 2027-10-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 137 studies testing acetaminophen in Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 30 in Pain:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This parallel, assessor blind, placebo-controlled, stratified, randomized study will investigate the effects of everyday pain on cognition and mobility in otherwise healthy individuals.
This study consisted of 3 visits. Visit 1 (Day1, Screening), minimum (min) of 7 days and maximum (max) of 28 days gap followed by Visit 2 (Day 2, pain-state assessment), a recovery period of min of 2 days and max of 30 days followed by Visit 3 (Day 3, pain-free assessment). Participants received treatment once only on Visit 2.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be administered test product (containing 500 mg paracetamol and 65 mg caffeine). Two tablets will be taken orally once with 200 mL (milliliters) of water.
Drug: Paracetamol and caffeine
Participants will be administered test product (containing 500 mg paracetamol). Two tablets will be taken orally once with 200 mL of water.
Drug: Paracetamol
Participants will be administered reference product (placebo to match Paracetamol 665mg sustained release tablets). Two tablets will be taken orally once with 200 mL of water.
Other: Placebo
Drug pages: Acetaminophen · Caffeine
Test product containing 500 mg paracetamol and 65 mg caffeine
Test product containing 500 mg paracetamol
Placebo to match paracetamol 665mg sustained release tablets
Change From Pain Free State (Day 3) in Error Adjusted Simple Reaction Time (SRT) in the Pain State (Day 2)
Error adjusted SRT was one of the main outcomes of the Axon Sports Priming Application. The Axon Sports Priming Application is a computerized test performed on a tablet device that measures cognitive performance, namely psychomotor speed. Axon sports test assessment included 1. Pain-state assessment performed at Visit 2 (Day 2 pre-treatment assessment and post-treatment assessment 1hour \[hr\] ± 15 minutes \[mins\] post-dosing) and 2. Pain-free assessment performed at Visit 3 (Day 3).
Time frame: At Day 2 (pre and post-treatment) and Day 3 of the study
Change From Pain-free State (Day 3) in Reaction Time in the Pain State (Day 2)
The reaction time of five-choice reaction time task (provided by Cambridge Cognition) was measured. In five-choice reaction time task, all the participants hold down a button at the bottom of the screen till a yellow spot appears in one of the five circles at the top of the screen. Participants then released the button and touch inside of the circle where the yellow spot appeared as quickly as they can. The median duration, between the onset of the stimulus and the release of the button, was recorded as reaction time. Calculated for correct, assessed trials where the stimulus appeared in any one of five locations.
Time frame: At Day 2 (pre and post-treatment) and Day 3 of the study
Change From Pain-free State (Day 3) in Number of One Touch Stockings (OTS) of Cambridge Assessment Problems (on Which the First Box Choice Made Was Correct) in the Pain State (Day 2)
OTS was a measure of executive function and takes approximately 10 minutes to complete. The participant was shown two displays containing three coloured balls. The displays were presented in such a way that they can easily be perceived as stacks of coloured balls held in stockings or socks suspended from a beam. There was a row of numbered boxes along the bottom of the screen. The test administrator first demonstrated to the participant how to use the balls in the lower display to copy the pattern in the upper display, and completed one demonstration problem, where the solution requires one move. The participant then completed three further problems, one each of two moves, three moves, and four moves. Next, the participant was shown further problems, and participants worked out in their head how many moves the solutions to these problems required, and then touch the appropriate box at the bottom of the screen to indicate their response.
Time frame: At Day 2 (pre and post treatment) and Day 3 of the study
Change From Pain-free State (Day 3) in Attention Switching Task (AST) Congruency Cost in the Pain State (Day 2)
AST was a measure of executive attention. The test displayed an arrow which can appear on either side of the screen and can point in either direction. Each trial displayed a cue at the top of the screen that indicates whether to press the right or left button. Some trials displayed congruent stimuli (e.g. arrow on the right side of the screen pointing to the right) whereas other trials display incongruent stimuli which require a higher cognitive demand (e.g. arrow on the right side of the screen pointing to the left). The AST congruency cost was the difference between the median latencies of response (from stimulus appearance to button press) on the trials that were congruent versus the trials that were incongruent. It was calculated by subtracting the median of congruent from incongruent latency. A positive score indicated response was faster on congruent trials and a negative score indicated response was faster on incongruent trials.
Time frame: At Day 2 (pre and post treatment) and Day 3 of the study
Change From Pain-free State (Day 3) in Spatial Working Memory (SWM) Between Errors in the Pain State (Day 2)
SWM task was a measure of working memory. The task involved number of coloured squares (boxes) being shown on the screen. The aim of this test was to find one blue token in the boxes shown to the participants by process of elimination and used these to fill up an empty column on the right-hand side of the screen. The number of boxes gradually increased up to a maximum of eight boxes to search and the colour and position of the boxes changed from trial to trial. SWM between errors was defined as times the participant revisited a box in which a token has previously been found. This was calculated for trials of four, six and eight tokens.
Time frame: At Day 2 (pre and post treatment) and Day 3 of the study
Change From Pain-free State (Day 3) in Rapid Visual Information Processing A Prime (RVPA) in the Pain State (Day 2)
RVP task was measures of attention. A white box appeared in the centre of the computer screen, inside which digits, from 2 to 9, appeared in a pseudo-random order, at the rate of 100 digits per minute. Participants were requested to detect target sequences of digits (for example, 2-4-6, 3-5-7, 4-6-8) and to register responses using the press pad. The RVPA (A prime) was the signal detection measure of sensitivity to the target, regardless of response tendency (the expected range will be 0.00 to 1.00; bad to good). RVP metric was a measure of how good the subject was at detecting target sequences.
Time frame: At Day 2 (pre and post treatment) and Day 3 of the study
Change From Pain-free State (Day 3) in Grip Force in Pain State (Day 2)
This task was a measure of grip strength. The participant held the dynamometer in their dominant hand and the arm was swung from above the head to by the side of the body. If the dominant arm or hand was painful then the non-dominant hand was used. The participant was instructed to assert maximum effort during the squeezing motion and maintain it for about 4 seconds using a metronome. Participant conducted the movement 4-times (1 practice effort and 3 test efforts) and there was a 1-minute recovery period between each effort.
Time frame: At Day 2 (pre and post-treatment) and Day 3 of the study
Change From Pain-free State (Day 3) in Time to Standing in Pain State (Day 2)
Time to standing provides a simple assessment of physical mobility. From a seated position with arms crossed so that the right hand is placed on the left shoulder and the left hand on the right shoulder, participants stood to a fully erect stature in as short a time as possible. Time to standing recorded which was measured using a stopwatch. Participants conducted the same movement 3-times continuously as a practice effort and 5-times continuously as a test effort at each visit. There was a 1-minute rest between the practice and test effort.
Time frame: At Day 2 (pre and post treatment) and Day 3 of the study
Change From Pain-free State (Day 3) in Ground Reaction Force (GRF) in Pain State (Day 2)
From a seated position with arms crossed so that the right hand is placed on the left shoulder and the left hand on the right shoulder, participants stood to a fully erect stature in as short a time as possible. Participants conducted the same movement 3-times continuously as a practice effort and 5-times continuously as a test effort at each visit. There was a 1-minute rest between the practice and test effort. GRF was measured during the movement analyzed using a force plate interfaced with a computer.
Time frame: At Day 2 (pre and post treatment) and Day 3 of the study
Change From Pain-free State (Day 3) in Contact Phase in Pain State (Day 2)
Participants performed a walking assessment in comfortable walking shoes to measure gait parameter contact phase. An athletic movement analysis system (Optojump, Microgate) was utilized which set up over a 15 meters (m) length of track with only the 5-10m section measured and analysed. Participants were instructed to walk the 15m length a minimum of 6 times (3 practice and a minimum of 3 test walks) always entering the 15m length with the same foot first. The foot (left or right) entering the 5-10m section first was recorded by visual assessment of the Optojump operator for the test walks. Test walks were repeated until there were 3 walks in which the participants have entered the 5-10m section with the same foot first.
Time frame: At Day 2 (pre and post treatment) and Day 3 of the study
Change From Pain-free State (Day 3) in Stride Length in Pain State (Day 2)
Participants performed a walking assessment in comfortable walking shoes to measure gait parameter stride length. An athletic movement analysis system (Optojump, Microgate) was utilized which set up over a 15 meters (m) length of track with only the 5-10m section measured and analysed. Participants were instructed to walk the 15m length a minimum of 6 times (3 practice and a minimum of 3 test walks) always entering the 15m length with the same foot first. The foot (left or right) entering the 5-10m section first was recorded by visual assessment of the Optojump operator for the test walks. Test walks were repeated until there were 3 walks in which the participants have entered the 5-10m section with the same foot first.
Time frame: At Day 2 (pre and post treatment) and Day 3 of the study
Change From Pain-free State (Day 3) in Walking Speed in Pain State (Day 2)
Participants performed a walking assessment in comfortable walking shoes to measure gait parameter walking speed over 5-10m for each foot. An athletic movement analysis system (Optojump, Microgate) was utilized which set up over a 15 meters (m) length of track with only the 5-10m section measured and analysed. Participants were instructed to walk the 15m length a minimum of 6 times (3 practice and a minimum of 3 test walks) always entering the 15m length with the same foot first. The foot (left or right) entering the 5-10m section first was recorded by visual assessment of the Optojump operator for the test walks. Test walks were repeated until there were 3 walks in which the participants have entered the 5-10m section with the same foot first.
Time frame: At Day 2 (pre and post-treatment) and Day 3
All participants were recruited at a single center from the United Kingdom.
| Milestone | Paracetamol and Caffeine | Paracetamol | Placebo |
|---|---|---|---|
| Started | 6 | 7 | 8 |
| Completed | 6 | 6 | 6 |
| Not completed | 0 | 1 | 2 |
| Withdrew: Other (not specified) | 0 | 1 | 2 |
Error adjusted SRT was one of the main outcomes of the Axon Sports Priming Application. The Axon Sports Priming Application is a computerized test performed on a tablet device that measures cognitive performance, namely psychomotor speed. Axon sports test assessment included 1. Pain-state assessment performed at Visit 2 (Day 2 pre-treatment assessment and post-treatment assessment 1hour \[hr\] ± 15 minutes \[mins\] post-dosing) and 2. Pain-free assessment performed at Visit 3 (Day 3).
| milliseconds (msec) | Paracetamol and Caffeine | Paracetamol | Placebo |
|---|---|---|---|
| Change from pain-free state at Day 2 pre-treatment | 0.05 (0.0 to 0.2) | 0.07 (0.0 to 0.8) | 0.06 (0.0 to 0.2) |
| Change from pain-free state at Day2 post-treatment | 0.04 (0.0 to 0.4) | 0.01 (0.0 to 0.3) | 0.00 (-0.2 to 0.1) |
The reaction time of five-choice reaction time task (provided by Cambridge Cognition) was measured. In five-choice reaction time task, all the participants hold down a button at the bottom of the screen till a yellow spot appears in one of the five circles at the top of the screen. Participants then released the button and touch inside of the circle where the yellow spot appeared as quickly as they can. The median duration, between the onset of the stimulus and the release of the button, was recorded as reaction time. Calculated for correct, assessed trials where the stimulus appeared in any one of five locations.
| msec | Paracetamol and Caffeine | Paracetamol | Placebo |
|---|---|---|---|
| Change from pain-free state at Day 2 pre-treatment | 2.00 (-17.5 to 36.0) | -1.75 (-41.0 to 170.5) | -1.00 (-6.5 to 18.5) |
| Change from pain-free state at Day2 post-treatment | 25.75 (-11.5 to 83.5) | 12.50 (-65.5 to 26.0) | -8.00 (-28.0 to 24.5) |
OTS was a measure of executive function and takes approximately 10 minutes to complete. The participant was shown two displays containing three coloured balls. The displays were presented in such a way that they can easily be perceived as stacks of coloured balls held in stockings or socks suspended from a beam. There was a row of numbered boxes along the bottom of the screen. The test administrator first demonstrated to the participant how to use the balls in the lower display to copy the pattern in the upper display, and completed one demonstration problem, where the solution requires one move. The participant then completed three further problems, one each of two moves, three moves, and four moves. Next, the participant was shown further problems, and participants worked out in their head how many moves the solutions to these problems required, and then touch the appropriate box at the bottom of the screen to indicate their response.
| OTS of correct first box choice | Paracetamol and Caffeine | Paracetamol | Placebo |
|---|---|---|---|
| Change from pain-free state at Day 2 pre-treatment | -2.67 ± 3.077 | 0.00 ± 1.095 | -0.20 ± 1.789 |
| Change from pain-free state at Day2 post-treatment | -1.83 ± 1.941 | 2.17 ± 1.835 | -1.40 ± 2.702 |
AST was a measure of executive attention. The test displayed an arrow which can appear on either side of the screen and can point in either direction. Each trial displayed a cue at the top of the screen that indicates whether to press the right or left button. Some trials displayed congruent stimuli (e.g. arrow on the right side of the screen pointing to the right) whereas other trials display incongruent stimuli which require a higher cognitive demand (e.g. arrow on the right side of the screen pointing to the left). The AST congruency cost was the difference between the median latencies of response (from stimulus appearance to button press) on the trials that were congruent versus the trials that were incongruent. It was calculated by subtracting the median of congruent from incongruent latency. A positive score indicated response was faster on congruent trials and a negative score indicated response was faster on incongruent trials.
| msec | Paracetamol and Caffeine | Paracetamol | Placebo |
|---|---|---|---|
| Change from pain-free state at Day 2 pre-treatment | -3.25 (-44.5 to 46.5) | 46.25 (-22.5 to 99.5) | 2.50 (-4.0 to 113.5) |
| Change from pain-free state at Day2 post-treatment | -8.25 (-44.0 to 43.5) | 23.00 (-5.0 to 104.0) | 22.50 (-171.5 to 113.5) |
SWM task was a measure of working memory. The task involved number of coloured squares (boxes) being shown on the screen. The aim of this test was to find one blue token in the boxes shown to the participants by process of elimination and used these to fill up an empty column on the right-hand side of the screen. The number of boxes gradually increased up to a maximum of eight boxes to search and the colour and position of the boxes changed from trial to trial. SWM between errors was defined as times the participant revisited a box in which a token has previously been found. This was calculated for trials of four, six and eight tokens.
| SWM between errors | Paracetamol and Caffeine | Paracetamol | Placebo |
|---|---|---|---|
| Change from pain-free state at Day 2 pre-treatment | -9.33 ± 18.747 | 25.17 ± 29.075 | 13.80 ± 23.994 |
| Change from pain-free state at Day2 post-treatment | 4.83 ± 22.248 | 13.50 ± 23.193 | -9.80 ± 32.920 |
RVP task was measures of attention. A white box appeared in the centre of the computer screen, inside which digits, from 2 to 9, appeared in a pseudo-random order, at the rate of 100 digits per minute. Participants were requested to detect target sequences of digits (for example, 2-4-6, 3-5-7, 4-6-8) and to register responses using the press pad. The RVPA (A prime) was the signal detection measure of sensitivity to the target, regardless of response tendency (the expected range will be 0.00 to 1.00; bad to good). RVP metric was a measure of how good the subject was at detecting target sequences.
| msec | Paracetamol and Caffeine | Paracetamol | Placebo |
|---|---|---|---|
| Change from pain-free state at Day 2 pre-treatment | -0.04 (-0.1 to 0.0) | 0.00 (0.0 to 0.0) | -0.03 (-0.1 to 0.0) |
| Change from pain-free state at Day2 post-treatment | -0.02 (-0.1 to 0.0) | -0.01 (-0.1 to 0.0) | 0.00 (0.0 to 0.0) |
This task was a measure of grip strength. The participant held the dynamometer in their dominant hand and the arm was swung from above the head to by the side of the body. If the dominant arm or hand was painful then the non-dominant hand was used. The participant was instructed to assert maximum effort during the squeezing motion and maintain it for about 4 seconds using a metronome. Participant conducted the movement 4-times (1 practice effort and 3 test efforts) and there was a 1-minute recovery period between each effort.
| Kilogram (Kg) | Paracetamol and Caffeine | Paracetamol | Placebo |
|---|---|---|---|
| Change from pain-free state at Day 2 pre-treatment | -1.98 ± 5.505 | -3.87 ± 3.792 | -1.70 ± 3.533 |
| Change from pain-free state at Day2 post-treatment | 0.68 ± 2.384 | -2.80 ± 3.059 | -0.46 ± 1.365 |
Time to standing provides a simple assessment of physical mobility. From a seated position with arms crossed so that the right hand is placed on the left shoulder and the left hand on the right shoulder, participants stood to a fully erect stature in as short a time as possible. Time to standing recorded which was measured using a stopwatch. Participants conducted the same movement 3-times continuously as a practice effort and 5-times continuously as a test effort at each visit. There was a 1-minute rest between the practice and test effort.
| Seconds | Paracetamol and Caffeine | Paracetamol | Placebo |
|---|---|---|---|
| Change from pain-free state at Day 2 pre-treatment | 0.10 (-0.4 to 0.2) | 0.13 (-0.2 to 0.3) | 0.09 (0.0 to 0.3) |
| Change from pain-free state at Day2 post-treatment | -0.01 (-0.2 to 0.5) | -0.08 (-0.3 to 0.4) | 0.04 (-0.2 to 0.6) |
From a seated position with arms crossed so that the right hand is placed on the left shoulder and the left hand on the right shoulder, participants stood to a fully erect stature in as short a time as possible. Participants conducted the same movement 3-times continuously as a practice effort and 5-times continuously as a test effort at each visit. There was a 1-minute rest between the practice and test effort. GRF was measured during the movement analyzed using a force plate interfaced with a computer.
| Newtons | Paracetamol and Caffeine | Paracetamol | Placebo |
|---|---|---|---|
| Change from pain-free state at Day 2 pre-treatment | 3.35 ± 11.781 | -19.80 ± 43.788 | 3.75 ± 11.214 |
| Change from pain-free state at Day2 post-treatment | 4.21 ± 8.295 | -13.85 ± 47.387 | 3.08 ± 12.064 |
Participants performed a walking assessment in comfortable walking shoes to measure gait parameter contact phase. An athletic movement analysis system (Optojump, Microgate) was utilized which set up over a 15 meters (m) length of track with only the 5-10m section measured and analysed. Participants were instructed to walk the 15m length a minimum of 6 times (3 practice and a minimum of 3 test walks) always entering the 15m length with the same foot first. The foot (left or right) entering the 5-10m section first was recorded by visual assessment of the Optojump operator for the test walks. Test walks were repeated until there were 3 walks in which the participants have entered the 5-10m section with the same foot first.
| Seconds | Paracetamol and Caffeine | Paracetamol | Placebo |
|---|---|---|---|
| Change from pain-free state at Day 2 pre-treatment | 0.03 (0.0 to 0.1) | 0.03 (0.0 to 0.1) | 0.00 (0.0 to 0.0) |
| Change from pain-free state at Day2 post-treatment | 0.03 (-0.0 to 0.1) | 0.02 (-0.0 to 0.1) | 0.01 (-0.02 to 0.03) |
Participants performed a walking assessment in comfortable walking shoes to measure gait parameter stride length. An athletic movement analysis system (Optojump, Microgate) was utilized which set up over a 15 meters (m) length of track with only the 5-10m section measured and analysed. Participants were instructed to walk the 15m length a minimum of 6 times (3 practice and a minimum of 3 test walks) always entering the 15m length with the same foot first. The foot (left or right) entering the 5-10m section first was recorded by visual assessment of the Optojump operator for the test walks. Test walks were repeated until there were 3 walks in which the participants have entered the 5-10m section with the same foot first.
| Centimeter | Paracetamol and Caffeine | Paracetamol | Placebo |
|---|---|---|---|
| Change from pain-free state at Day 2 pre-treatment | -0.06 ± 0.098 | -0.08 ± 0.123 | -0.02 ± 0.038 |
| Change from pain-free state at Day2 post-treatment | -0.04 ± 0.084 | -0.06 ± 0.116 | -0.04 ± 0.037 |
Participants performed a walking assessment in comfortable walking shoes to measure gait parameter walking speed over 5-10m for each foot. An athletic movement analysis system (Optojump, Microgate) was utilized which set up over a 15 meters (m) length of track with only the 5-10m section measured and analysed. Participants were instructed to walk the 15m length a minimum of 6 times (3 practice and a minimum of 3 test walks) always entering the 15m length with the same foot first. The foot (left or right) entering the 5-10m section first was recorded by visual assessment of the Optojump operator for the test walks. Test walks were repeated until there were 3 walks in which the participants have entered the 5-10m section with the same foot first.
| meters/second | Paracetamol and Caffeine | Paracetamol | Placebo |
|---|---|---|---|
| Change from pain-free state at Day 2 pre-treatment | -0.11 ± 0.112 | -0.10 ± 0.180 | -0.02 ± 0.052 |
| Change from pain-free state at Day2 post-treatment | -0.10 ± 0.105 | -0.07 ± 0.157 | -0.03 ± 0.043 |
Collected over Up to 61 days. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Paracetamol and Caffeine | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| Paracetamol | 0/7 (0%) | 0/7 (0%) | 1/7 (14.3%) |
| Placebo | 0/8 (0%) | 0/8 (0%) | 2/8 (25%) |
| Event | Paracetamol and Caffeine | Paracetamol | Placebo |
|---|---|---|---|
| Pharyngeal erythemaRespiratory, thoracic and mediastinal disorders | 0/6 | 1/7 | 0/8 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 0/6 | 0/7 | 1/8 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 0/6 | 0/7 | 1/8 |
| Age, Continuous(Years) | Paracetamol and Caffeine | Paracetamol | Placebo | Total |
|---|---|---|---|---|
| Mean | 27.8 ± 4.83 | 30.0 ± 9.45 | 40.0 ± 15.87 | 33.2 ± 12.31 |
| Sex: Female, Male(Participants) | Paracetamol and Caffeine | Paracetamol | Placebo | Total |
|---|---|---|---|---|
| Female | 4 | 5 | 5 | 14 |
| Male | 2 | 2 | 3 | 7 |
| Race (NIH/OMB)(Participants) | Paracetamol and Caffeine | Paracetamol | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 2 | 2 | 1 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 2 | 3 |
| White | 3 | 5 | 4 | 12 |
| More than one race | 0 | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2016 to primary completion in Feb 2017, 3 months.
Results were first posted in Aug 2018, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Acetaminophen · Caffeine